Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Trial Type:  Treatment
Results 1-25 of 221 for your search:
Start Over
Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GU002, NCI-2016-00963, NCT03070886
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Modifications to Radical Prostatectomy in Improving Outcomes in Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 11-096, NCI-2011-02377, NCT01407263
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PrTK03, NCI-2012-01912, NCT01436968
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Status: Active
Phase: Phase III
Type: Treatment
Age: Any age
Trial IDs: CR100797, NCI-2013-00686, 2011-005243-28, 212082PCR3010, NCT01517802
Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-497, NCI-2012-01144, NCT01617161
Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Lesions
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 55 to 75
Trial IDs: PCa003, NCI-2013-01791, NCT01657942
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR106935, NCI-2016-00117, 2015-003007-38, 56021927PCR3003, NCT02531516
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR107614, NCI-2016-00191, 2015-000735-32, 56021927PCR3002, NCT02489318
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 9785-CL-0335, NCI-2016-00640, 2015-003869-28, NCT02677896
ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17777, NCI-2016-01849, 2015-002590-38, NCT02799602
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081DC00007, NCI-2017-00284, NCT02987543
Ultra-hypofractionated Stereotactic Body Radiation Therapy with or without Short Course Degarelix in Treating Patients with Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 16-1686, NCI-2017-00741, NCT03056638
Magnetic Resonance Spectroscopic Imaging in Finding Tumors in Patients with Stage I-III Prostate Cancer Planning to Undergo Prostate Surgery
Status: Active
Phase: Phase II, Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 2006-0516, NCI-2011-00517, PC061612, NCT00464724
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Start Over